These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27765877)

  • 1. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
    Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
    Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
    Salavisa M; Serrazina F; Ladeira AF; Correia AS
    Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
    Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
    J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
    Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report.
    Berkovich R
    Mult Scler Relat Disord; 2017 Oct; 17():123-127. PubMed ID: 29055441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
    Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
    Coerver EME; Bourass A; Wessels MHJ; van Kempen ZLE; Jasperse MMS; Tonino BAR; Barkhof F; Mostert J; Uitdehaag BMJ; Killestein J; Strijbis EMM
    Mult Scler Relat Disord; 2023 Jun; 74():104706. PubMed ID: 37068370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.